Tinnitus control by dopamine agonist XXXX in @entity26811 @entity1 : a randomized, placebo-controlled, double-blind study.

@entity1 @entity1032 @entity191 @entity392 @entity399 @entity26811
OBJECTIVES/HYPOTHESIS: Since the concept of @entity392 dopaminergic pathway emerged, studies have been proposed to investigate if dopaminergic agents influence @entity392 . We hypothesized that @entity399 , an agonist on D2/D3 receptors, may antagonize @entity392 in the @entity26811 @entity1 (in the frequency range of 250 to 8,000 Hz) in a dose schedule accepted for the treatment of @entity191 in elderly @entity1 . STUDY DESIGN: We designed a randomized, prospective, placebo-controlled and double-blind trial. METHODS: Forty @entity26811 @entity1 aged 50 years or older with subjective @entity392 were randomized to two groups (20 @entity1 in both). @entity1 in the drug group took @entity399 over a period of 4 weeks according to a treatment schedule as follows: week 1, 0.088 mg t.i.d.; week 2, 0.18 mg t.i.d.; week 3, 0.7 mg t.i.d.; week 4, 0.18 mg t.i.d. over 3 days and 0.088 mg t.i.d. the rest of the week. @entity1 in the second group received placebo. Determination of subjective grading of @entity392 , the @entity1032 inventory (THI) questionnaire and electrocochleography (ECOG) examinations served as the end points. Subjective audiometry was used to produce secondary data. A significant improvement in @entity392 annoyance is found in the group treated with @entity399 versus placebo with respect to @entity392 and a @entity392 greater than 30 dB. However, neither ECOG nor subjective pure-tone threshold audiometry revealed any change in hearing threshold in response to either @entity399 or placebo. CONCLUSIONS: @entity399 is an effective agent against subjective @entity392 associated with @entity26811 at a dose schedule used for the treatment of @entity191 . The drug did not change hearing threshold.
